Symptoms and General Pathology

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Rare Diseases

Recurrence

Melanoma

Glioblastoma

Glioma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Astrocytoma

Neoplasms, Neuroepithelial

Neoplasms, Glandular and Epithelial

Neuroendocrine Tumor

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

Pembrolizumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.

pembrolizumab

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab.

Pembrolizumab has been approved by the U.S. Food and Drug Administration for the treatment of patients with Glioblastoma and Melanoma The Expanded Access Program (EAP) for this medicine in the U.S. is closed. The EAP will continue outside the U.S.

Expanded Access for Pembrolizumab (MK-3475)

Expanded Access for Pembrolizumab (MK-3475) to Patients With Melanoma or Glioblastoma / Glioma After Failed Standart Therapy, at High Mutational Load Which is Confirmed by the Results of Molecular-genetic Analysis of Tumor Tissue.

Center Trials & Treatment

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Expanded Access for Pembrolizumab (MK-3475)	NCT03311542	Melanoma (Skin) Melanoma Recurr... Glioblastoma Mu... Glioblastoma by... Glioma of Brain	pembrolizumab	18 Years - 80 Years	Center Trials & Treatment
Expanded Access for Pembrolizumab (MK-3475)	NCT03311542	Melanoma (Skin) Melanoma Recurr... Glioblastoma Mu... Glioblastoma by... Glioma of Brain	pembrolizumab	18 Years - 80 Years	Center Trials & Treatment

Spots Global Cancer Trial Database for glioblastoma by gene expression profile